Prostate transglutaminase: A unique transglutaminase and its role in prostate cancer

Biomarkers in Medicine

Volumn 5, Issue 3, 2011, Pages 285-291

  Jiang, Wen G ^a   Ablin, Richard J ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

cell invasion; epithelial mesenchymal transition; melanoma differentiation associated gene 7 IL 24; prostate cancer; prostate transglutaminse; RON; TGM4; tumor endothelial interactions

Indexed keywords

INTERLEUKIN 24; PROSTATE TRANSGLUTAMINASE 4; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

CANCER CELL; CELL INTERACTION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; HUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TGM 4 GENE;

BIOLOGICAL MARKERS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTERLEUKINS; MALE; PROSTATIC NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 79958855444     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.36     Document Type: Review

References (57)

1. Folk JE, Chung SI: Molecular and catalytic properties of transglutaminases. Adv. Enzymol. 38, 109-191 (1973).
2. Lorand L, Graham RM: Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell. Biol. 4, 140-156 (2003). (Pubitemid 36172696)
3. Grant FJ, Taylor DA, Sheppard PO et al.: Molecular cloning and characterization of a novel transglutaminase cDNA from a human prostate cDNA library. Biochem. Biophys. Res. Commun. 203, 1117-1123 (1994).
4. Ho KC, Quarmby VE, French FS, Wilson EM: Molecular cloning of rat prostate transglutaminase complementary DNA. The major androgen-regulated protein DP1 of rat dorsal prostate and coagulating gland. J. Biol. Chem. 267, 12660-12667 (1992).
5. Gentile V, Grant FJ, Porta R, Baldini A: Localization of the human prostate transglutaminase (type IV) gene (TGM4) to chromosome 3p2133-p22 by fluorescence in situ hybridization. Genomics 27, 219-220 (1995).
6. Dubbink HJ, de Waal L, van Haperen R, Verkaik NS, Trapman J, Romijn JC: The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterization. Genomics 51, 434-444 (1998). (Pubitemid 28413210)
7. Dubbink HJ, Verkaik NS, Faber PW, Trapman J, Schroder FH, Romijn JC: Tissue-specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem. J. 315, 901-908 (1996). (Pubitemid 26147620)
8. Dubbink HJ, Hoedemaeker RF, van der Kwast TH, Schroder FH, Romijn JC: Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern. Lab. Invest. 79, 141-150 (1999). (Pubitemid 29110645)
9. Wilson EM, French F: Biochemical homology between rat dorsal prostate and coagulating gland. Purification of a major androgen-induced protein. J. Biol. Chem. 255, 10946-10953 (1980). (Pubitemid 11170876)
10. Hayashi N, Sugimura Y, Kawamura J, Donjacour AA, Cunha GR: Morphological and functional heterogeneity in the rat prostatic gland. Biol. Reprod. 24, 24-32 (1981).
11. Williams-Ashman HG: Transglutaminases and the clotting of mammalian seminal fluids. Mol. Cell. Biochem. 58, 51-61 (1984). (Pubitemid 14167040)
12. Ablin RJ, Whyard T: Identification and biological relevance of spermatozoal transglutaminase. Experientia 47, 277-279 (1991). (Pubitemid 21892817)
13. Ablin RJ, Bartkus JM, Gonder MJ, Polgar J: Factors contributing to suppression of tumor-host responsiveness. In:Human Tumor Markers-Biology and Clinical Applications. Cimino F, Birkmayer CD, Pimental E, Klavins JV, de Gruyter SFW (Eds).Berlin, Germany, 279-299 (1987).
14. Ablin RJ, Bartkus JM, Polgar J: Effect of human seminal plasma on the lytic activity of natural killer cells and presumptive identification of participant macromolecules. Am. J. Reprod. Immunol. 24, 15-21 (1990).
15. Whyard TC, Ablin RJ: A tissue type transglutaminase in human seminal plasma. Amer. J. Reprod. Immunol. 38, 391-399 (1997). (Pubitemid 27489986)
16. Ablin RJ, Gonder MJ: Male accessory sexual glands secretions and their antithetical role in immunosurveillance. In:Protides of the Biological Fluids. Peeters H (Ed.).Pergamon Press Ltd, Oxford, UK, 271-276 (1985).
17. Davies G, Ablin RJ, Mason MD, Jiang WG: Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J. Exp. Therapeut. Oncol. 6, 257-264 (2007). (Pubitemid 46789726)
18. Jiang WG, Ablin R, Douglas-Jones A, Mansel RE: Expression of transglutaminases and the clinical significance in human breast cancer. Oncology Rep. 10, 2039-2044 (2003).
19. Prins GS, Woodham C, Lepinske M, Birch L: Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinology 132, 2387-2398 (1993). (Pubitemid 23156886)
20. An G, Meka CS, Bright SP, Veltri RW: Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression,and down-regulation in metastatic prostate cancer. Urology 54, 1105-1111 (1999).
21. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hemstreet GP 3rd: Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 89, 412-423 (2000). (Pubitemid 30489892)
22. Jiang WG, Ablin RJ, Kynaston HG, Mason MD: Expression of the prostate type transglutaminase (TGase-4) in clinical prostate cancer (Abstract).Presented at: American Association for Cancer Research, 98th Annual Meeting. Los Angeles, CA, USA, 14-18 April 2007
23. Cho SY, Choi K, Jeon JH, Kim CW et al.: Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer. Exp. Mol. Med. 42, 310-318 (2010).
24. Cho SY, Jeon JH, Kim CW et al.: Monoclonal antibodies to human transglutaminase 4 Hybridoma (Larchmt.) 29, 263-267 (2010).
25. Ablin RJ, Whyard TC: Immunobiological implications of select bioactive molecules in the prostate with a known and and unknown target. In:The Prostate as an Endocrine Gland. Farnsworth WE, Ablin RJ (Eds).CRC Press, Inc., Boca Raton, FL, USA, 149-172 (1990).
26. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 152, 1-9 (1998). (Pubitemid 28028039)
27. Trapman J, Cleutjens KB: Androgen-regulated gene expression in prostate cancer. Semin. Cancer Biol. 8, 29-36 (1997). (Pubitemid 27417427)
28. Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD: The androgen receptor: genetic considerations in the development and treatment of prostate cancer. J. Mol. Med. 77, 419-426 (1999). (Pubitemid 29302706)
29. Jiang WG, Ye L, Ablin RJ, Kynaston HG, Mason MD: The prostate transglutaminase, TGase-4, coordinates with the HGFL/ MSP-RON system in stimulating the migration of prostate cancer cells. Int. J. Oncol. 37, 413-418 (2010).
30. Jiang WG, Abliln RJ, Mason MD: The impact of prostate transglutaminase (TGase-4) on the micromotion of prostate cancer cells. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010
31. Jiang WG, Ablin RJ, Kynaston HG, Mason MD: The prostate transglutaminase (TGase-4) impacts the cell-matrix adhesion of prostate cancer cells, an electric cell-substrate sensing study. Presented at: American Society for Cell Biology, 47th Annual Meeting. Washington, DC, USA, 1-5 December 2007
32. Jiang WG, Ablin R: Expression of transglutaminase in human prostate cancer cells and the role in motogen induced migration and matrix adhesion. FASEB J. 17, C288 (2003).
33. Boyer B, Thiery JP: Epithelium-mesenchyme interconversion as example of epithelial plasticity. APMIS 101, 257-268 (1993). (Pubitemid 23210029)
34. Mathias RA, Simpson RJ: Towards understanding epithelial-mesenchymal transition: a proteomics perspective. Biochim. Biophys. Acta. 1794, 1325-1331 (2009).
35. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
36. Iwatsuki M, Mimori K, Yokobori T et al.: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101, 293-299 (2009).
37. Shao M, Cao L, Shen C et al.: Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 69, 9192-9201 (2009).
38. Ablin RJ, Jiang WG: Prostate transglutaminase (TGase-4) induces epithelial-mesenchymal transition (EMT) in prostate cancer cells. Presented at: 4th International Conference Epithelial- Mesenchymal Transition. Tucson, AZ, USA, 23-28 September 2008
39. Nicolson GL, Birdwell CR, Brunson KW, Robbins JC: Cellular interactions in the metastatic process. Prog. Clin. Biol. Res. 9, 237-244 (1976).
40. Alonso-Varona A, Palomares T, Bilbao P, Calle Y, Castro B, Barberá-Guillem E: Tumor-host interaction in non-random metastatic pattern distribution. Bull. Cancer 83, 27-38 (1996). (Pubitemid 26041649)
41. Iiizumi M, Mohinta S, Bandyopadhyay S, Watabe K: Tumor-endothelial cell interactions: therapeutic potential. Microvasc. Res. 74, 114-120 (2007). (Pubitemid 350051022)
42. Jiang WG, Ablin RJ, Kynaston HG, Mason MD: The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc. Res. 77, 150-157 (2009).
43. Emdad L, Lebedeva IV, Su Z-Z et al.: Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24 Cancer Biol. Therapy 8, 391-400 (2009).
44. Saito Y, Miyahara R, Gopalan B et al.: Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated-7 (MDA-7)/ interleukin-24 (IL-24) gene. Cancer Gene Ther. 12, 238-247 (2005). (Pubitemid 40315183)
45. Ablin RJ, Kynaston HG, Mason MD, Jiang WG: Prostate type transglutaminase (TGase-4) antagonizes the anti-tumor action of MDA-7/IL-24 in prostate cancer. J. Transl. Med. 9, 49 (2011).
46. Han S, Stuart LA, Degen SJF: Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry 30, 9768-9780 (1991).
47. Ronsin C, Muscatelli F, Mattei MG, Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8, 1195-1202 (1993). (Pubitemid 23129841)
48. Welm AL, Sneddon JB, Taylor C et al.: The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc. Natl Acad. Sci. USA 104, 7570-7575 (2007). (Pubitemid 47185947)
49. Sakamoto O, Iwama A, Amitani R et al.: Role of macrophage-stimulating protein and its receptor, RON tyrosine kinase, in ciliary motility. J. Clin. Invest. 99, 701-709 (1997). (Pubitemid 27097672)
50. Davies G, Watkins G, Sanders AJ et al.: A hammerhead ribozyme transgene to transglutaminase-4 increases the level of its substrate psoriasin and reduces the invasive capacity of prostate cancer cells in vitro. Presented at: American Association for Cancer Research, 96th Annual Meeting, Anaheim, CA, USA, 16-20 April 2005
51. Madsen P, Rasmussen HH, Leffers H et al.: Molecular cloning, occurrence, and expression of a novel partially secreted protein 'psoriasin' that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. 97, 701-712 (1991).
52. Rautiainen J, Rytkonen M, Parkkinen S et al.: cDNA cloning and protein analysis of a bovine dermal allergen with homology to psoriasin. Invest. Dermatol. 105, 660-663 (1995).
53. Watson PH, Leygue ER, Murphy LC: Psoriasin (S100A7).Int. J. Biochem. Cell. Biol. 30, 567-571 (1998).
54. Alowami S, Qing G, Emberley E, Snell L, Watson PH: Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol. 3, 1 (2003).
55. Moog-Lutz C, Bouillet P, Regnier CH et al.: Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22 Int. J. Cancer 63, 297-303 (1995).
56. Jiang WG, Watkins G, Douglas-Jones A, Mansel RE: Psoriasin is aberrantly expressed in human breast cancer and is related to clinical outcomes. Int. J. Oncol. 25, 81-85 (2004).
57. Ruse M, Lambert A, Robinson N, Ryan D, Shon KJ, Eckert RL: S100A7, S100A10, and S100A11 are transglutaminase substrates. Biochemistry 40, 3167-3173 (2001). (Pubitemid 32205361)